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Abstract
BACKGROUND—The incidence of meningococcal disease is currently at historic lows in the 
United States; however, incidence remains highest among infants aged <1 year. With routine use 
of Haemophilus influenzae type b and pneumococcal vaccines in infants and children in the 
United States, Neisseria meningitidis remains an important cause of bacterial meningitis in young 
children.
METHODS—Data were collected from active, population- and laboratory-based surveillance for 
N meningitidis conducted through Active Bacterial Core surveillance during 2006 through 2012. 
Expanded data collection forms were completed for infant cases identified in the surveillance area 
during 2006 through 2010.
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RESULTS—An estimated 113 cases of culture-confirmed meningococcal disease occurred 
annually among infants aged <1 year in the United States from 2006 through 2012, for an overall 
incidence of 2.74 per 100 000 infants. Among these cases, an estimated 6 deaths occurred. 
Serogroup B was responsible for 64%, serogroup C for 12%, and serogroup Y for 16% of infant 
cases. Based on the expanded data collection forms, a high proportion of infant cases (36/58, 62%) 
had a smoker in the household and the socioeconomic status of the census tracts where infant 
meningococcal cases resided was lower compared with the other Active Bacterial Core 
surveillance areas and the United States as a whole.
CONCLUSIONS—The burden of meningococcal disease remains highest in young infants and 
serogroup B predominates. Vaccines that provide long-term protection early in life have the 
potential to reduce the burden of meningococcal disease, especially if they provide protection 
against serogroup B meningococcal disease.
Meningococcal disease is a serious but rare infectious disease. In the United States, the 
incidence of meningococcal disease has declined since a peak of disease in the late 1990s; 
declines have been observed among all age groups and serogroups.1,2 In 2012, the incidence 
of meningococcal disease was at a historic low (0.15 per 100 000 persons)3; however, 
incidence remained highest among infants aged <1 year.1–3
Meningitis in infants and young children can be caused by a wide range of bacteria. In 
infants aged <2 months, group B Streptococcus causes most cases in the United States.4 
Listeria monocytogenes is also seen in this age group. For infants and children aged 2 to 23 
months, Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae 
also are important causes of bacterial meningitis and sepsis.4 With routine use of H 
influenzae type b and pneumococcal vaccines for infants and children in the United States, 
incidence due to both pathogens has been reduced, leaving N meningitidis as one of the most 
important causes of bacterial meningitis in infants and young children in the United 
States.4,5
This report describes the current epidemiology and burden of meningococcal disease in 
infants aged <1 year in the United States and potential risk factors for transmission to this 
vulnerable group. These data are key to informing future meningococcal disease vaccination 
strategies in the United States.
METHODS
Surveillance
Active, population- and laboratory-based surveillance for disease caused by N meningitidis 
was conducted from January 1, 2006, through December 31, 2012, as part of Active 
Bacterial Core surveillance (ABCs). ABCs is supported by the US Centers for Disease 
Control and Prevention (CDC) as part of its Emerging Infections Program Network, as 
described elsewhere.6 The surveillance area included California (3 San Francisco Bay area 
counties), Colorado (5 Denver area counties), Connecticut (statewide), Georgia (statewide), 
Maryland (statewide), Minnesota (statewide), New Mexico (statewide), Oregon (statewide), 
New York (15 Rochester and Albany area counties), and Tennessee (11 urban counties in 
2002–2009, 20 counties in 2010–2012). In 2012, the total population under surveillance was 
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42.8 million, or 13.6% of the US population. Approximately 530 000 infants <1 year resided 
in the ABCs surveillance area during 2012.
A case of meningococcal disease was defined as isolation of N meningitidis from a normally 
sterile site (eg, blood or cerebrospinal fluid [CSF]) in a surveillance area resident. 
Epidemiologic and clinical information was abstracted from medical records. Outcome of 
illness was based on the patient's status at the time of hospital discharge; no information was 
collected on whether the death was attributed to N meningitidis infection. Information on 
assessment for sequelae before discharge and sequelae present at discharge are not routinely 
collected by ABCs. Regular laboratory audits were conducted to identify cases missed 
during routine surveillance.
The following hierarchical definition was used to classify a single syndrome for cases: a 
patient was defined as having meningitis if a clinical diagnosis of meningitis had been 
entered into the patient's medical record or if N meningitidis was isolated from CSF, 
pneumonia if pneumonia was entered into the patient's medical record and N meningitidis 
was isolated from blood and pleural fluid, septic arthritis if N meningitidis was isolated from 
joint fluid, and isolated bacteremia if N meningitidis was isolated from blood and no 
localizing clinical syndrome was described.
Expanded Data Collection
Expanded case report forms were completed for cases of meningococcal disease in infants 
aged <1 year presenting from January 1, 2006, until December 31, 2010. The expanded 
chart review forms included variables for medical history (gestational age and weight, 
congenital anomalies and underlying conditions, sequelae at discharge) and social history 
(breastfeeding history, day care attendance, household smoking status, maternal and paternal 
age). Sites were encouraged to also review public health investigation records to improve 
the completeness of data collected on the expanded case report form. Additional information 
on medical and social history variables was collected from case birth certificates and by 
geocoding cases to collect socioeconomic data from the census tract where the case resided.
Eight of the 10 ABCs sites participated in the expanded chart review and data collection 
(Colorado, Georgia's Atlanta Metropolitan Statistical Area, Maryland, Minnesota, New 
Mexico, New York, Oregon, and Tennessee). This study was determined to be nonhuman 
subject's research, exempt from human subject's regulations by the CDC Human Research 
Protection Office. This study also was determined to be exempt from human subjects' 
regulations by the participating ABCs surveillance sites. This study was reviewed and 
approved by the institutional review boards of the Georgia Metropolitan Statistical Areas, 
Maryland Department of Health and Mental Hygiene, and Johns Hopkins Bloomberg School 
of Public Health.
Laboratory Methods
Serogrouping of N meningitidis was performed at state public health laboratories, after 
which the isolates were sent to the CDC, where slide agglutination serogrouping and 
serogroup-specific real-time polymerase chain reaction (real-time PCR) were performed.7 If 
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the CDC slide agglutination or PCR testing confirmed the state serogroup result, that result 
was used as the final serogroup. If the CDC slide agglutination and PCR both differed from 
the state serogroup, the CDC result was used as the serogroup. If an isolate was nonviable or 
contaminated on arrival at the CDC after sending 2 times, the result from the state laboratory 
was used.
Statistical Analyses
Incidence rates were calculated by using US census data for the ABCs sites. Population 
denominators by month of life for infants aged <1 year were calculated by obtaining US 
census estimates for the number of infants <1 year of age in the surveillance area for each 
year studied and dividing by 12. Missing race data were multiply imputed by using 
sequential regression imputation methods.8 Estimates of the number of cases and deaths in 
the 50 states were calculated, standardizing for race. For rate calculations, an ABCs site was 
included only if data were collected for the complete year. Oregon has reported higher rates 
of serogroup B and overall meningococcal disease because of hyperendemic serogroup B 
disease that was first reported in 1994.9,10 We verified that the Oregon clonal outbreak was 
not consistent with disease patterns in other states by comparing disease incidence in Oregon 
with the 50 states by using reports from the National Notifiable Diseases Surveillance 
System. From 2006 to 2012, Oregon reported a meningococcal disease incidence of 0.91 per 
100 000 persons through the National Notifiable Diseases Surveillance System. The other 49 
states reported incidence of 0.14 to 0.53 per 100 000 persons (CDC, unpublished data). 
Accordingly, incidence was standardized by race to the US population by using incidence 
excluding Oregon. Cases in Oregon were then added back in for the final standardized 
incidence rate and estimated annual burden of disease in the United States. For all other 
analyses, data presented includes cases from Oregon unless otherwise noted. The 95% 
confidence interval (CI) around the standardized rate was calculated by using a method 
derived from the relationship between Poisson distribution and the γ distribution.11 
Incidence rates are reported as cases per 100 000 persons.
RESULTS
Surveillance
Between 2006 and 2012, 127 cases of meningococcal disease were identified in infants aged 
<1 year in the surveillance area for an average annual incidence of 3.30 cases per 100 000 
infants (range 2.63–4.89). Incidence ranged from 1.11 per 100 000 infants in Connecticut to 
10.45 cases per 100 000 infants in Oregon. The higher incidence observed in Oregon was 
driven by its hyperendemic serogroup B disease; 24 (71%) of the 34 infant cases reported 
from Oregon were serogroup B, compared with 58 (62%) of 93 infant cases in the other 
ABCs sites.
Seven (6%) patients died; 5 patients who died had meningitis and 2 patients had isolated 
bacteremia. Eighty-eight (69%) cases were male. Seventeen (14%) were black, 94 (74%) 
were white, and 30 (24%) were reported as Hispanic. The median age was 5 months (range, 
11–361 days). Five (4%) cases occurred in infants aged <1 month. In 53 (42%) cases, N 
meningitidis was isolated from the CSF, including 19 cases that had growth in both CSF and 
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blood cultures. The remaining 55 cases had growth in blood cultures only (n = 51; 40%) or 
from joints (n = 4; 4%). Among the surviving cases, 102 (86%) were hospitalized; the 
median length of hospitalization was 7 days (range, 2–373 days). Seasonal variation 
occurred with the highest proportion of cases reported during the months of February to July 
(n = 82; 65%). Serogroup was available for all isolates: 82 (64%) were serogroup B, 15 
(12%) serogroup C, 21 (16%) serogroup Y, 7 (6%) serogroup W, and 2 (2%) nongroupable.
An estimated 113 cases of culture-confirmed meningococcal disease occurred annually 
among infants aged <1 year in the United States from 2006 to 2011, for an overall incidence 
of 2.74 per 100 000 infants (Table 1). Among these cases, an estimated 6 deaths occurred 
each year. Approximately 23% of infant meningococcal disease cases could be prevented 
with a serogroup C and Y vaccine if protection was achieved by age 4 months; a vaccine 
that protects against serogroup B by 4 months of age would have the potential to prevent 
~37% of infant cases. A combined serogroup B, C, and Y vaccine would have the potential 
to prevent up to 63% of infant meningococcal disease cases in the United States (Fig 1).
Expanded Data Collection
Expanded case report forms were completed for 81 (99%) of 82 cases, birth certificate data 
were available for 79 (96%) cases, and census tract data were available for all 82 cases in 
infants <1 year from 2006 to 2010 in the participating sites. Most cases occurred among 
healthy full-term infants. Gestational age and birth weight were available for 78 cases; the 
median gestational age was 38 weeks (range 29–42 weeks) and the median birth weight was 
3192 g (range 1389–4960 g). Three infants were reported to have congenital anomalies or 
abnormal conditions at birth (intrauterine growth restriction and drug exposure, congenital 
cytomegalovirus infection, and meningomyelocele/spina bifida).
Data on social history variables were less complete. Among cases with available data, 8 
(19.5%) of 41 cases had a history of current breastfeeding; an additional 11 cases had a 
history of ever being breastfed. On the birth certificate, 35% of infants were breastfed at 
birth. Daycare attendance was reported by 17 (26%) of 65 cases. A high proportion of cases 
(36/58, 62%) had a smoker in the household. The median household size was 4 persons 
(range, 2–14), with a median of 2 adults (range, 1–9) and 2 children (range, 0–8). Most cases 
(67/75, 89%) reported no sequelae at discharge. Of those patients who survived, 2 patients 
had skin necrosis, 3 patients had seizures, 2 patients had hearing loss, and 1 additional 
patient failed an audiology screen but final audiology results were not available. Six cases 
had unknown or insufficient information to determine if sequelae were present.
The median maternal age was 22.9 years (range, 14.0–39.7 years) and the median paternal 
age was 27.0 years (range, 17–54 years). Thirty-four percent of case mothers had less than a 
high school education, 34% were high school or equivalent graduates, and 23% had some 
college or higher-level education. The principal source of payment for the delivery was 
Medicaid for 53%, private insurance for 13%, self-pay for 6%, and unknown for 28%.
Socioeconomic indicators from the census tract where the cases resided were compared with 
other census tracts in the ABCs areas and the United States as a whole (Table 2). In general, 
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the census tracts in which the cases resided had lower socioeconomic status than the other 
ABCs areas and the United States as a whole.
DISCUSSION
During the study period, the incidence of meningococcal disease was at historic lows in the 
United States (0.15 per 100 000 persons),3 however incidence remained highest among 
infants aged <1 year (2.74 per 100 000 infants). In the United States, ~60% of disease 
among infants aged <1 year is caused by serogroup B,1,2 which is not contained in recently 
licensed meningococcal vaccines for infants and toddlers.
Meningococcal disease can be devastating; 5% to 10% of children with meningococcal 
disease do not survive and another 10% to 20% experience long-term sequelae, such as 
hearing loss, limb loss, and neurologic deficits.12
Infants may be at increased risk for meningococcal disease for several reasons. The infant 
immune system is immature, which increases the risk for infections in general; traditional 
risk factors for meningococcal disease (ie, complement component deficiencies and 
asplenia) are rarely identified in infants, and typically present later in life. Other risk factors 
that are more generally associated with an increased risk for meningococcal disease include 
close contact with a case, living in crowded conditions, active and passive smoking, and 
antecedent viral infections.13–18 Our findings are consistent with the results of previous 
studies and indicate these risk factors also increase risk of disease in infants.14,19–21 In 
particular, our study found a high proportion of infant meningococcal disease cases with 
exposure to cigarette smoke (62%), compared with 35% of children in the United States who 
live in homes where residents or visitors smoke in the home on a regular basis.22 In our 
study, we also found that the median age of the case mothers was lower than the average age 
at first birth for US mothers in 2006 (22.9 years versus 25.0 years),23 and the socioeconomic 
status of the census tracts where infant meningococcal cases resided was lower compared 
with the other ABCs areas and the United States as a whole. Low socioeconomic status is 
often considered a marker for other risk factors (eg, smoking and household crowding),24,25 
but lower maternal age may be associated with increased contact of infant cases with 
adolescents or young adults who are the main carriers of N meningitis and serve as 
reservoirs of transmission to other age groups.21,26
Three meningococcal conjugate vaccines have been licensed for use in infants and toddlers 
in the United States, protecting against 2 of the 3 major serogroups that cause disease 
(serogroups C and Y, but not B). The Advisory Committee on Immunization Practices 
recommends vaccination of infants and toddlers who are at increased risk for disease, but 
does not recommend routine vaccination of all infants.27 This decision was based on the 
current low burden of disease and the low proportion of meningococcal cases that are 
preventable with vaccines that do not protect against serogroup B, which limits the potential 
impact of a routine meningococcal vaccination program in infants in the United States. A 
multicomponent serogroup B vaccine (Bexsero; Novartis, Basel, Switzerland) was recently 
licensed in Europe, Australia, and Canada and is currently under consideration for inclusion 
in infant immunization programs in these countries. Two vaccines to prevent serogroup B 
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meningococcal disease are in late-stage clinical development in the United States; however, 
licensure of a vaccine that protects against serogroup B in infants in the United States is 
likely several years away.
The meningococcal conjugate vaccines currently available in the United States and the 
vaccines for serogroup B currently under development require multiple doses early in life to 
provide protection to infants. Because the largest burden of disease in <1-year-olds occurs in 
children 0 through 6 months of age, many will be too young to have received the minimum 
2 or 3 doses of vaccine that likely will be needed to prevent disease. Consideration of other 
programmatic interventions may be necessary to protect these youngest infants because 
direct protection of most infants with these vaccines is not possible. These could potentially 
include a maternal vaccination program with a vaccine that protects against serogroup B and 
continuing to improve vaccination coverage with 2 doses of conjugate meningococcal 
vaccine in adolescents who are the main carriers of N meningitidis. Serogroup B vaccines 
have the potential to offer an important advance in the fight against meningococcal disease. 
However, research is needed to better understand how to optimally implement these 
vaccination programs.
The overall burden of meningococcal disease in the United States is substantially lower than 
in other countries. However, the epidemiology of meningococcal disease is dynamic, and 
close monitoring of trends is needed to accurately assess the benefit of adding 
meningococcal vaccines to the routine infant schedule. Vaccines that provide long-term 
protection early in life have the potential to reduce the burden of meningococcal disease, 
especially if they provide protection against serogroup B meningococcal disease.
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WHAT'S KNOWN ON THIS SUBJECT
Meningococcal disease is a serious but rare infectious disease. In 2012, the incidence of 
meningococcal disease was at a historic low in the United States; however, incidence 
remained highest among infants aged <1 year.
WHAT THIS STUDY ADDS
This report describes the epidemiology and burden of meningococcal disease in infants 
aged <1 year in the United States and potential risk factors for transmission to this 
vulnerable group. These data are key to informing future meningococcal disease 
vaccination strategies.
MacNeil et al. Page 10














Average annual cases of meningococcal disease by month of life and serogroup, United 
States, 2006–2012. ABCs cases from 2006 to 2012 are directly standardized to the race 
distribution of the US population.
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TABLE 1
Average Annual Incidence of Meningococcal Disease in Children <1 year: United States, 2006–2012
Age, mo Serogroup B Serogroup C Serogroup Y Total
a
Incidence (95% CI) Incidence (95% CI) Incidence (95% CI) Incidence (95% CI)
0–1 1.96 (0.98–3.52) 0.02 (0.00–0.70) 0.64 (0.17–1.71) 2.81 (1.61–4.57)
2–3 2.48 (1.37–4.16) 0.29 (0.04–1.13) 0.21 (0.01–1.05) 3.45 (2.12–5.31)
4–5 2.08 (1.10–3.60) 0.39 (0.06–1.36) 0.87 (0.28–2.06) 3.34 (2.04–5.19)
6–7 1.79 (0.87–3.29) 0.39 (0.06–1.36) 0.60 (0.16–1.62) 2.95 (1.73–4.72)
8–9 1.56 (0.74–2.95) 0.39 (0.09–1.24) 0.19 (0.00–1.03) 2.34 (1.31–3.91)
10–11 0.66 (0.19–1.72) 0.12 (0.00–0.87) 0.73 (0.21–1.86) 1.54 (0.72–2.91)
Total 1.76 (1.35–2.25) 0.27 (0.13–0.49) 0.54 (0.32–0.85) 2.74 (2.22–3.34)
ABCs cases from 2006 through 2012 directly standardized to the race distribution of the US population.
a
Includes other serogroups (eg, serogroup W, nongroupable).
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TABLE 2
Socioeconomic Measures for Persons Residing in Census Tracts With Infant Meningococcal Disease Cases 
Compared With All US Census Tracts and Census Tracts in Participating ABCs Areas, 2006–2010 American 
Community Survey 5-Year Estimates
Case Census Tracts, 
Median
United States, All 
Census Tracts
Participating ABCs Area 
Census Tracts
Persons aged ≥ 16 who are unemployed, % 8.6 7.9 7.4
Median household income $41 831 $51 914 $55 815
Households with income <$25 000, % 29.1 23.5 20.7
Households with income ≥$200 000, % 0.9 4.2 4.6
All persons living below US poverty line, % 15.3 13.8 12.0
Persons aged ≥25 y with less than a high school education, % 13.4 14.9 13.6
Persons aged ≥25 y with a Bachelor's degree or higher, % 17.8 27.9 27.8
homes worth ≥$500 000, % 1.7 12.5 10.5
Homes worth ≥$750 000, % 0.1 5.1 3.7
All households containing >1 person per room, % 2.3 3.1 2.1
Census tract population living in a rural area, % 0 22.4 19.0
GINI index
a
 of income inequality 0.405 0.467 0.425
a
A measurement of the income distribution of a country's residents. This number, which ranges between 0 and 1 and is based on residents' net 
income, helps define the gap between the rich and the poor, with 0 representing perfect equality and 1 representing perfect inequality.
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